Daewoong Pharmaceutical’s Botulinum Toxin Product Nabota Breaks Sales Record in First Half of 2023
Daewoong Pharmaceutical announced a groundbreaking achievement as their botulinum toxin product, Nabota, achieved record-breaking sales in the first half of this year. With total sales amounting to 75.3 billion won from January to June, Nabota has emerged as the top-selling domestic toxin among manufacturers in the industry.
The sales figures for Nabota have been consistently rising, with an impressive growth from 50.4 billion won in 2020 to 79.6 billion won in 2021 and a staggering 142 billion won in 2022. Notably, foreign sales accounted for 80% of the total sales in the previous year, amounting to 109.9 billion won.
In response to the skyrocketing demand for Nabota, Daewoong Pharmaceutical has made a strategic decision to construct a third factory dedicated exclusively to its production. The completion of Factory 3 is expected in 2024, and it is projected to increase production levels by a remarkable 260%, reaching a capacity of 13 million vials for injections.
Vice President of Daewoong Pharmaceutical, Park Seong-soo, expressed his optimism stating, “Nabota’s exceptional sales growth in the first half of this year has secured its position as the leading botulinum toxin manufacturer in Korea. With this momentum, we envision Nabota evolving into a globally renowned product.” This achievement further solidifies Daewoong Pharmaceutical’s commitment to innovation and expansion in the aesthetic pharmaceutical market.
The remarkable success of Nabota not only demonstrates its popularity among domestic and international consumers but also highlights Daewoong Pharmaceutical’s dedication to providing high-quality products that meet the needs of their customers. As the brand continues to flourish, it is poised to establish itself as a global player in the field of poison manufacture.
As the demand for Nabota continues to grow, Daewoong Pharmaceutical’s relentless pursuit of excellence and their commitment to meet market demands have positioned them on a trajectory for continued success and industry leadership.
Reporter: Jang Eun-pa
[비즈니스포스트] Daewoong Pharmaceutical’s botulinum toxin product Nabota set an all-time sales record in the first half of this year.
Daewoong Pharmaceutical announced on the 27th that sales of Nabota from January to June this year reached 75.3 billion won.
▲ Daewoong Pharmaceutical’s botulinum toxin product Nabota (pictured) achieved record sales in the first half of this year. <대웅제약>
Daewoong Pharmaceutical said, “Nabota recorded the highest sales figure among domestic toxin manufacturing companies in the first half of this year,” and added, “We expect annual sales to also reach the highest in 2023.”
Nabota sales are increasing rapidly from 50.4 billion won in 2020 to 79.6 billion won in 2021 and 142 billion won in 2022. Last year, foreign sales amounted to 109.9 billion won, accounting for 80% of total the sale.
Daewoong Pharmaceutical decided to build a third factory to respond to Nabota’s steep sales.
Factory 3 is expected to be completed in 2024, and once the factory is complete, production will increase by 260% to 13 million vials (dose based on one injection).
Park Seong-soo, Vice President of Daewoong Pharmaceutical, said, “Nabota finally became the first in sales among Korean botulinum toxin manufacturers through a rapid increase in the first half of this year. “It will grow to be the world’s leading poison,” he said. Reporter Jang Eun-pa
#Daewoong #Pharmaceutical #Nabotas #sales #year #KRW #billion #among #domestic #toxin #manufacturing #companies